文献速递浆细胞疾病

p53缺失增强克隆性多发性骨髓瘤细胞的肿瘤起始潜能与耐药性

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells.
PubMed 文献 · Blood Adv · 2023-01-01

研究探讨17p13缺失(含TP53缺失)高危多发性骨髓瘤中p53缺失对肿瘤起始细胞的影响。发现p53敲除增加肿瘤起始多发性骨髓瘤细胞的频率和耐药性,RNA测序显示Notch信号通路激活及ID1/ID2上调。敲低ID1或HES-1或γ-分泌酶抑制剂(GSI)处理显著降低p53敲除细胞的克隆生长,小样本骨髓瘤标本中GSI降低del17p样本克隆生长。

要点

  • p53缺失增加肿瘤起始多发性骨髓瘤细胞的频率和耐药性
  • p53敲除细胞中Notch信号通路激活、ID1/ID2基因上调
  • GSI或敲低ID1/HES-1降低p53敲除细胞克隆生长,小样本del17p标本中GSI亦降低克隆生长

核心结论

  • Notch信号通路和ID1表达是p53敲除多发性骨髓瘤细胞中肿瘤起始细胞扩增所必需的。
  • 这些发现提示GSI可能对p53突变多发性骨髓瘤患者具有特异性活性。

研究设计与样本

  • 研究采用p53敲除(p53-KO)细胞模型,并进行RNA测序(RNA-seq)分析。
  • 使用小样本多发性骨髓瘤标本评估GSI对del17p与非del17p样本克隆生长的影响。

主要发现

  • p53缺失增加肿瘤起始多发性骨髓瘤细胞(TIC)的频率和耐药性。
  • RNA-seq显示p53-KO细胞中Notch信号通路显著激活及ID1/ID2基因上调。
  • 敲低ID1或HES-1表达或GSI处理显著降低p53-KO细胞的克隆生长,但不降低p53野生型细胞的克隆生长。
  • 小样本多发性骨髓瘤标本中,GSI处理降低del17p样本的克隆生长,但不降低非del17p样本的克隆生长。
  • 过表达Notch胞内结构域(NICD)可逆转GSI处理的效果。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor relapse and drug resistance are major factors that limit the curability of multiple myeloma (MM). New regimens have improved overall MM survival rates, but patients with high-risk features continue to have inferior outcomes. Chromosome 17p13 deletion (del17p) that includes the loss of the TP53 gene is a high-risk cytogenetic abnormality and is associated with poor clinical outcomes owing to relatively short remissions and the development of pan-drug resistant disease. Increased relapse rates suggest that del17p enhances clonogenic growth, and we found that the loss of p53 increased both the frequency and drug resistance of tumor-initiating MM cells (TICs). Subsequent RNA sequencing (RNA-seq) studies demonstrated significant activation of the Notch signaling pathway and upregulation of inhibitor of DNA binding (ID1/ID2) genes in p53-knock out (p53-KO) cells. We found that the loss of ID1 or HES-1 expression or treatment with a gamma-secretase inhibitor (GSI) significantly decreased the clonogenic growth of p53-KO but not p53 wild-type cells. GSI treatment in a small set of MM specimens also reduced the clonogenic growth in del17p samples but not in non-del17p samples. This effect was specific as overexpression of the Notch intracellular domain (NICD) rescued the effects of GSI treatment. Our study demonstrates that the Notch signaling and ID1 expression are required for TIC expansion in p53-KO MM cells. These findings also suggest that GSI may be specifically active in patients with p53 mutant MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chang YT, Chiu I, Wang Q, et al. Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells. Blood Adv. 2023. PMID: 37042949. doi:10.1182/bloodadvances.2022009387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。